2026-10-19T00:34:16Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/101172026-10-18T20:25:22Zopenairedrivercom_ebyu_10000col_ebyu_10001

First-Line Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from TurkeyMıdık, Mustafa MuratŞahin, GökhanDurukan, Bekir MertKuş, FatihHaşimoğlu Gürün, KübraÜnal, SinanMirili, CemKaran, CananHendem, EnginŞakalar, TeomanAydoğan, MirayKöylü, BahadırSever, NadiyeKaya, Bahattin EnginKuş, TülayŞencan, CanberkErdoğan, Atike PınarYaşar, Hatime ArzuKarakaş, HilalYıldız, OğuzhanYılmaz, BahiddinAlan, MuratÇetin, BülentTuran, NedimEryılmaz, Melek KarakurtArtaç, MehmetÜnek, İlkay TuğbaSelçukbiricik, FatihŞendur, Mehmet AliYıldırım, Hasan ÇağrıYalçın, Şuayibdurvalumabhepatocellular carcinomaimmunotherapyreal worldsafetytremelimumabticilimumabadrenal insufficiencyadultadvanced canceragedantineoplastic activityarterial chemoembolizationArticlebone metastasisChild Pugh scoreclinical articleclinical outcomeclinical practicecohort analysiscolitisdiarrheadrug efficacydrug safetydrug withdrawalECOG Performance Statusfemalefirst-line treatmentfollow uphepatitis BBackground: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. Although the STRIDE regimen (durvalumab plus tremelimumab) has demonstrated an overall survival benefit in clinical trials, real-world evidence remains limited, particularly in Turkish clinical practice. This study aimed to evaluate the effectiveness and safety of first-line STRIDE therapy in patients with unresectable HCC treated in routine clinical practice. Methods: We conducted a retrospective multicenter study including patients with unresectable HCC who received first-line durvalumab plus tremelimumab through the Turkish national Early Access Program across 18 oncology centers. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and exploratory Cox regression analyses were performed to evaluate baseline prognostic factors. Results: Thirty-two patients were included. The median PFS was 7.25 months (95% CI, 3.68–22.29), and the median OS was 11.43 months (95% CI, 4.50–not reached). The underlying liver disease etiology was non-viral in 53.1% of patients, hepatitis B virus in 40.6%, and hepatitis C virus in 6.3%. Grade ≥ 3 treatment-related adverse events occurred in fewer than 10% of patients. Conclusions: In this multicenter real-world cohort, first-line durvalumab plus tremelimumab appeared to be a feasible treatment option and was generally well tolerated in patients with unresectable HCC. However, given the retrospective design, small sample size, and absence of a control group, these findings should be interpreted cautiously and require confirmation in larger prospective comparative studies. © 2026 by the authors.Multidisciplinary Digital Publishing Institute (MDPI)2026Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/10117https://doi.org/10.3390/jcm151559972077-0383enJournal of Clinical Medicineinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/10117